Navigation Links
Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
Date:5/19/2010

y other marketed ERT for Type 1 Gaucher disease.

VPRIV was approved by the Food and Drug Administration (FDA) on February 26, 2010, as a long-term treatment for adult and pediatric patients with Type 1 Gaucher disease. It has also been granted accelerated assessment by the European Medicines Agency (EMA) in the European Union (EU). Shire expects to launch VPRIV in the EU in the second half of 2010, and in other countries beginning in 2011.

"It is a tremendous honor to be recognized by NORD," said Sylvie Gregoire, President of Shire HGT. "This award embodies the spirit of our organization-every employee at Shire is dedicated to developing and bringing forward new products, services and support offerings which can make a positive impact on patients' daily lives. We look forward to collaborating with NORD on many other important initiatives in the future."

Important Safety Information for VPRIV

The most serious adverse reactions seen with VPRIV were hypersensitivity reactions. Infusion-related reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. The most commonly observed symptoms of infusion-related reactions were: headache, dizziness, low or high blood pressure, nausea, tiredness and weakness, and fever. Generally the infusion-related reactions were mild and, in treatment-naive patients, onset occurred mostly during the first 6 months of treatment and tended to occur less frequently with time. Adverse reactions more commonly seen in pediatric patients compared to those observed in adult patients (>10% difference) include rash, upper respiratory tract infection, prolonged activated partial thromboplastin time, and fever.

As with all therapeutic proteins, there is a
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
2. Shires Replenished Portfolio Drives Excellent Quarterly Performance
3. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
4. Shire Supports Rare Disease Day 2010
5. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
6. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
7. Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
8. New Shire Board Member
9. Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
10. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
11. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... ... analysis and premium industry insights on the global resorcinol industry. The report highlights ... study of vivid market scenarios and analysis of primary and secondary inputs from ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... , July 30, 2015  With over 60,000 customers across the globe, ISN ... connect 450 hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... ... Headquartered in Dallas, TX ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Firstlogic, Inc. announced the general availability of ... Business Edition is designed to help organizations manage ... the necessary order and format to receive postal ... ,The program includes features designed to decrease processing ...
... Sonic Foundry, Inc. , today announced the addition of ... Peercy and Gary Weis. , ,The Madison-based media communications ... market experience of its board of directors with the ... next annual shareholders meeting, at which time they will ...
... believe that globalization is good for America overall despite ... substantial difference between thoughtfully embracing global free trade and ... affects businesses, communities and individual workers. , ,Dr. ... Rochester Institute of Technology and an expert on the ...
Cached Biology Technology:Preservation not protectionism 2Preservation not protectionism 3
(Date:7/31/2015)... 31 de julio de 2015 BGI llevará a ... ) del 22 al 25 de octubre de 2015, ... La conferencia celebra su décimo aniversario este año. Desde ... una de las reuniones anuales más influyentes del mundo ... de las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... , July 31, 2015 The 10 th ... held by BGI from October 22-25, 2015, in Shenzhen ... The conference is celebrating its 10 th anniversary this year. ... the world,s most influential annual meetings in the ,omics, fields, ... scientific gatherings. ICG-10 focuses on recent breakthroughs ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... range of bitter tastes before rejection compared to milk ... a test of bitterness rejection levels in chocolate, people ... -- milk chocolate with a bitter substance added to ... in food science. Dark chocolate fans had significantly higher ...
... the Susquehanna River just above Chesapeake Bay are nearly at ... large storms are already delivering increasingly more suspended sediment and ... Too many nutrients rob the Bay of oxygen ... disturbing the habitat of underwater plants crucial for aquatic life ...
... have secured funding for a piece of state-of-the-art equipment ... The team of researchers working at Leicester Royal Infirmary ... made in Switzerland. Its purchase was made ... and Allergy Research Association (MAARA) and the Maud Elkington ...
Cached Biology News:Bitter tastes quickly turn milk chocolate fans sour 2Increased sediment and nutrients delivered to bay as Susquehanna reservoirs near sediment capacity 2Increased sediment and nutrients delivered to bay as Susquehanna reservoirs near sediment capacity 3New equipment is breath of fresh air for children's lung researchers 2
Rabbit polyclonal to IL23 P19 ( Abpromise for all tested applications). Antigen: Synthetic 16 amino acid peptide from near the amino terminus of human IL23 P19 Entrez Gene ID: 51561 Swiss...
3M Imidazole Solution 125 ml...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
...
Biology Products: